1 **Title:**

2 Phenotypes associated with genetic determinants of type I interferon regulation in the UK Biobank: a
3 protocol

4

5	Authors	and	affiliations:

- 6 Bastien Rioux¹, Michael Chong^{2,3,4}, Rosie Walker⁵, Sarah McGlasson¹, Kristiina Rannikmäe⁶, Daniel
- 7 McCartney⁷, John McCabe^{8,9}, Robin Brown¹⁰, Yanick J Crow^{11,12}, David Hunt^{1*}, William Whiteley^{1,13*}

8

- 9 ¹ Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- ¹⁰ ² Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
- ³ Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
- ⁴ Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
- ⁵ Department of Psychology, University of Exeter, Exeter, United Kingdom
- ⁶Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, United
- 15 Kingdom
- ⁷ Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of
- 17 Edinburgh, Edinburgh, United Kingdom
- ⁸ School of Medicine, University College Dublin, Dublin, Ireland
- ⁹ Department of Medicine for the Elderly, Mater Misericordiae University Hospital, Dublin, Ireland
- 20 ¹⁰ Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
- 21 ¹¹ MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh,
- 22 United Kingdom
- ¹² Laboratory of Neurogenetics and Neuroinflammation, Institut Imagine, Université de Paris, Paris,
- 24 France

- ¹³ MRC Population Health Unit, Nuffield Department of Population Health, University of Oxford
- 26
- 27 * Last authors with equal contribution
- 28
- 29 **Corresponding author:**
- 30 Prof David Hunt
- 31 Centre for Clinical Brain Sciences, University of Edinburgh
- 32 Chancellor's Building, 49 Little France Cres, EH16 4SB
- 33 Edinburgh, UK
- 34 <u>david.hunt@ed.ac.uk</u>
- 35
- 36 **Keywords:** stroke, dementia, interferonopathy, lupus, inflammation, type I interferon, genetics,
- 37 variants, UK Biobank
- 38
- **Word count:** 3,987

40 ABSTRACT

Introduction: Type I interferons are cytokines involved in innate immunity against viruses. Genetic 41 42 disorders of type I interferon regulation are associated with a range of autoimmune and cerebrovascular 43 phenotypes. Carriers of pathogenic variants involved in genetic disorders of type I interferons are 44 generally considered asymptomatic. Preliminary data suggests, however, that genetically determined 45 dysregulation of type I interferon responses is associated with autoimmunity, and may also be relevant 46 to sporadic cerebrovascular disease and dementia. We aim to determine whether functional variants in 47 genes involved in type I interferon regulation and signalling are associated with the risk of 48 autoimmunity, stroke, and dementia in a population cohort. 49 Methods and analysis: We will perform a hypothesis-driven candidate pathway association study of 50 type I interferon-related genes using rare variants in the UK Biobank (UKB). We will manually curate 51 type I interferon regulation and signalling genes from a literature review and Gene Ontology, followed 52 by clinical and functional filtering. Variants of interest will be included based on pre-defined clinical 53 relevance and functional annotations (using LOFTEE, M-CAP and a minor allele frequency <0.1%). 54 The association of variants with 15 clinical and three neuroradiological phenotypes will be assessed 55 with a rare variant genetic risk score and gene-level tests, using a Bonferroni-corrected p-value 56 threshold from the number of genetic units and phenotypes tested. We will explore the association of 57 significant genetic units with 196 additional health-related outcomes to help interpret their relevance 58 and explore the clinical spectrum of genetic perturbations of type I interferon. 59 **Ethics and dissemination:** The UKB has received ethical approval from the North West Multicentre 60 Research Ethics Committee, and all participants provided written informed consent at recruitment. This 61 research will be conducted using the UKB Resource under application number 93,160. We expect to

62 disseminate our results in a peer-reviewed journal and at an international cardiovascular conference.

63 STRENGTHS AND LIMITATIONS OF THIS STUDY

- The UK Biobank is the largest whole-exome sequencing project to date, with marked power to 65 detect associations from a limited number of rare, functional variants.
- Our study will leverage current knowledge of interferon biology and genotype-phenotype

67 correlations in Mendelian diseases of type I interferon to test biologically plausible hypotheses.

- The UK Biobank includes phenotypes from multiple sources, which improves classification accuracy for several health outcomes such as stroke and dementia.
- We will carefully select genes and variants with strong evidence of biological relevance to

71 optimize the power of our analyses, which is particularly relevant for less common phenotypes

- 72 in the UK Biobank such as systemic lupus erythematosus.
- We will increase the specificity of predicted loss-of-function variants by using stringent sample
 quality control and filtering criteria.

75 **INTRODUCTION**

76 Interferons are a family of innate inflammatory cytokines primarily secreted by host cells in response to 77 viruses (type I: mainly interferon- α and - β ; type II: interferon- γ ; type III: interferon- λ). Interferon-78 stimulated genes are involved in a wide range of processes, namely cellular defence against pathogens, 79 apoptosis, nucleic acid degradation, and cell-to-cell communication [1]. Defects in type I interferon 80 homeostasis are associated with autoimmunity, being implicated in the pathogenesis of systemic lupus 81 erythematosus and other autoimmune disorders such as rheumatoid arthritis, Sjögren's syndrome, and 82 scleroderma [2]. Low-grade type I interferon upregulation may also contribute to sporadic 83 cerebrovascular disease and dementia. Preclinical data suggest type I interferon-related vascular 84 inflammation is an essential contributor to atherosclerosis and may be involved in cerebral small vessel 85 disease [3, 4]. Stroke risk is increased after long-term exposure to exogenous recombinant type I 86 interferon [4, 5], whereas white matter hyperintensities (a radiological manifestation of cerebral small 87 vessel disease), large vessel disease and stroke are more frequent in people with systemic lupus 88 ervthematosus as compared to the general population [6, 7]. 89 Genetic type I interferonopathies are a group of rare Mendelian autoinflammatory diseases 90 hypothesised to be caused by an upregulation of type I interferons. Affected individuals with Aicardi-91 Goutières syndrome, the first type I interferonopathy described, most frequently present in early 92 childhood with progressive encephalopathy, skin vasculopathy, and autoimmunity [8], in addition to 93 prominent white matter hyperintensities, calcifications and large vessel disease (aneurysms, arterial 94 calcifications, stenoses) on brain imaging [9]. Most, albeit not all (e.g., mutations in *IFIH1*, *STING* and COPA), pathogenic variants associated with type I interferonopathies result in a loss-of-function (LOF) 95 96 of key interferon negative regulators inherited as autosomal recessive traits. Carriers of such pathogenic 97 variants are generally considered asymptomatic, although growing evidence from case series suggests 98 they may also exhibit high expression of interferon-stimulated genes [10] and have mild

99 interferonopathy-related traits [11, 12]. Uncertainty remains, however, as to whether carriers of 100 pathogenic variants in genes involved in type I interferon signalling and regulation have an increased 101 risk of interferonopathy-related phenotypes such as autoimmunity, cerebrovascular disease, and 102 dementia. Moreover, the causal role of type I interferon in sporadic cerebrovascular disease and 103 dementia has not been comprehensively assessed in a population-based study [13], and whether 104 findings from preclinical studies and observations in conditions with impaired interferon homeostasis 105 translate to the general population is unclear. We will apply a candidate pathway approach to determine whether functional variants in genes 106

involved in type I interferon regulation and signalling are associated with clinical and neuroradiological interferonopathy phenotypes in the general population. We hypothesize that a subset of rare functional variants that result in an upregulation of the type I interferon cascade are associated with core interferonopathy phenotypes.

111

112 METHODS AND ANALYSIS

We will report our results using guidance from the Strengthening the Reporting of Genetic Association
Studies (STREGA) initiative [14], and present the protocol checklist in Supplemental methods 1. We
present a graphical abstract of our protocol in Figure 1.

116

117 Study population and exome extraction

118 We will use data from the UK Biobank (UKB), a large population-based cohort of 502,650 participants

119 mostly of white British ancestry who were aged 40-69 years when recruited from UK patient registries

120 between 2006 and 2010 (response rate: 5.5%) [15, 16]. We will consider individuals with whole-exome

sequencing based on the final exome data release (July 2022; n=469,807; 93.5% of participants). The

122 exome was sequenced in two batches composed of the first 50k participants (phase 1) and all other

samples (phase 2). Participants in the first phase were selected to enrich certain phenotypes, which may
lead to spurious associations given time-varying sequencing coverage if this batch effect is not
controlled (see below).

Genomic DNA samples were sent to the Regeneron Genetics Centre (Tarrytown, New York, USA) as part of a collaboration with the UKB and stored at -80°C. Genomic libraries with a mean fragment size of 200 base pairs (bp) were created enzymatically and tagged with barcodes of 10 bp before capture. Exome was obtained by next generation sequencing using the Illumina NovaSeq 6000 platform (S2 and S4 flow cells for the first and second phase, respectively) and a target-enrichment probe kit (IDT xGen® Exome Research Panel v1.0) to enable deep and uniform coverage of ~39 Mbp (19,396 genes).

133

134 Whole-exome sequencing data

135 We will use the multi-sample project-level VCF (pVCF) files made available by the UKB [17]. To 136 obtain these joint genotype data, raw sequencing outputs (FASTQs) were initially processed into 137 sample-level aligned sequences (CRAMs) with a standard protocol (the Original Quality Functionally 138 Equivalent; OOFE), which maps short sequences to the GRCh38 reference genome with alternate loci 139 and marks duplicate segments [18]. DeepVariant (v0.10.0) was used to call variants from sample-level 140 CRAMs and produce variant call data (gVCF) for each participant [19]. This calling approach uses a 141 deep convolutional neural network to determine the most likely genotype at each locus from the 142 reference genome, base reads and quality scores [20]. It outperforms existing state-of-the-art tools to 143 call single nucleotide variants (SNVs) and small insertions or deletions (indels; up to 50 bp by 144 definition), achieving high overall accuracy (>99.5%) [20, 21]. The variant call data set includes exome 145 capture targets and their immediate flanking regions (100 bp upstream and downstream of each target).

Sample-level variants were aggregated into joint genotype pVCF files with a standard analysis pipeline

146

147 (GLnexus v1.2.6) [19, 22]. 148 For quality control, we will exclude participants with a mismatch between their genetically 149 recorded and self-reported sex or with sex chromosome an euploidy ($\sim 0.2\%$). We will apply a set of 150 per-variant quality control metrics as previously employed for the UKB exome to analyse variants with 151 [23]: 152 i) individual and variant missingness <10%; Hardy Weinberg equilibrium p-value $>10^{-15}$; 153 ii) 154 iii) at least one sample per site with allele balance threshold >0.15 for SNVs and >0.20 for 155 small indels; 156 iv) minimum read coverage depth of seven for SNVs and 10 for indels. 157 We will also use a sequencing depth $\geq 10x$ in 90% of samples for our rare variant analysis, to prevent 158 spurious associations that may result from batch effect [24]. We will resolve haplotype phase with the 159 Segmented HAPlotype Estimation and Imputation Tools version 5 (SHAPEIT5 v1.0.0), which phases 160 rare variants from the UKB with high accuracy (switch error rate <5% with minor allele count >5) [25]. 161 162 **Genes of interest** 163 We will apply a hypothesis-driven candidate pathway approach of type I interferon-related genes by 164 adapting a previously described methodology [26]. We will consider for inclusion any gene encoding a 165 protein of interest belonging to one of the three following categories: 166 1. A negative regulator, positive regulator, or effector along the main signalling pathway of type I 167 interferon (Figure 2); 168 2. A protein directly affecting the activity of an interferon regulator or effector (e.g., E3 ubiquitin-169 protein ligase TRIM21 inhibits interferon regulatory factor 3, a transcription factor that controls

multiple type I interferon-inducing pathways; both proteins are therefore considered forinclusion);

172

3. A protein involved in genetic type I interferonopathies (see **Supplemental table 1**).

173 We did not consider regulatory proteins acting beyond the second order of regulation (e.g., regulators 174 of E3 ubiquitin-protein ligase TRIM21) to adequately balance the need to include important regulators 175 of type I interferon, while maintaining their specificity to type I interferon signalling. 176 We will produce a preliminary list of genes from i) recently published reviews on type I 177 interferon biology and ii) annotations in Gene Ontology [27]. We present herein both completed and 178 upcoming steps. First, we searched Ovid MEDLINE to identify reviews describing ≥ 2 proteins of 179 interest in physiological conditions. We used interferons (of any type to increase the sensitivity of our 180 search) and regulation as main concepts, in addition to a previously published hedge for reviews (**Table** 181 1) [28]. We queried MEDLINE from January 2000 onwards to only include recent reviews, and 182 conducted our search in English as we expected reviews in other languages to present similar 183 information. Our strategy yielded 194 records. A single author (BR) will screen records by title and 184 abstract, and include relevant articles after full-text reading. We will manually add four recent reviews 185 [8, 9, 29, 30] on genetic interferonopathies to ensure these genes are captured. A single author (BR) 186 will extract relevant proteins, their corresponding genes, and their presumed functions. 187 Second, we have queried the Gene Ontology resource to validate and enrich our gene set. Gene 188 Ontology provides curated gene-specific knowledge with functional annotation and hierarchical 189 relationships [27, 31, 32]. We extracted a list of 194 genes pertaining to 31 ontology terms relevant to 190 type I interferon (Supplemental table 2). We will validate presumed gene product function from

- 191 reviews and Gene Ontology on the UniProt platform [33] and the National Center for Biotechnology
- 192 Information (NCBI) Gene database [34] before assigning their function (e.g., negative regulator) and

193 level of action (e.g., downstream to receptors). Discrepancies will be resolved through consensus by

194 three authors with expertise in interferon biology (BR, SM, DH).

From this preliminary list of genes, we will only include those with ≥ 1 variant associated with a Mendelian disease through any effect on protein function to strengthen their biological relevance. We will search the Online Mendelian Inheritance in Man (OMIM) [35] and the NCBI ClinVar [36] clinical annotation databases for genotype-phenotype correlations. We will validate that all top 21 type I interferon-inducible genes in systemic lupus erythematosus are included in our list, and add missing items [37].

201

202 Variants of interest

We will include both SNVs and small indels in genes of interest with ≥1 of the following protein
effects: i) LOF, dominant-negative, or gain-of-function (GOF) disease-causing variants through an
autosomal dominant, recessive or X-linked inheritance [38], or ii) predicted LOF variants from
functional annotations. We will define disease-causing variants as those reported in ClinVar (as
pathogenic or likely pathogenic, excluding variants with conflicting interpretations of pathogenicity),
OMIM (as disease-causing), and from discussion with clinical experts in interferonopathies (DH, SM,
YC). The protein-level effect will be determined through comments and linked publications in ClinVar,

210 descriptions in OMIM or, if undetermined, inferred from resulting phenotype.

We will also define a second set of putative functional variants identified in UKB participants to increase our statistical power [39]. We will assess the functional impact of these variants on Ensembl with the Variant Effect Predictor (VEP), an online resource that returns annotations on the effect of variants on transcripts and proteins [40]. We will interpret variant pathogenicity with the Loss-Of-Function Transcript Effect Estimator (LOFTEE) and the Mendelian Clinically Applicable

216 Pathogenicity score (M-CAP v1.4). The LOFTEE filtering criteria will be used to annotate non-

Page 10 of 31

217 missense predicted LOF variants, as it provides a conservative filtering strategy to increase specificity 218 (e.g., removal of variants predicted to escape nonsense-mediated decay) and was used to annotate 219 variants in the Genome Aggregation Database (gnomAD; a public resource of ~126k high-quality 220 exomes from around the world that does not include UKB data) [41] and Genebass (a public resource 221 of exome-based genotype-phenotype associations within the UKB) [42]. The M-CAP score will be 222 used to interpret pathogenicity and nominate missense variants for inclusion [43]. This supervised 223 learning classifier incorporates nine established pathogenicity likelihood scores (namely SIFT and 224 PolyPhen-2) and achieves substantial reduction in the misclassification rate of known pathogenic 225 variants (<5%) as compared to other existing methods (26-38%) [43]. We will define predicted LOF 226 variants as either i) variants that inactivate a protein-coding gene through a premature stop codon, a 227 shift in the transcriptional frame or an alteration of essential splice-site nucleotides (from LOFTEE), or 228 ii) missense variants classified as likely pathogenic (from M-CAP). We will apply a minor allele 229 frequency (MAF) threshold <0.1% in both the UKB and gnomAD to lower the probability of including 230 benign variants and improve our statistical power. Using a more liberal MAF threshold of <1%, 8.03 231 million SNVs were identified in ~200k UKB participants, of which 5.4% (~450k) were predicted LOF 232 variants [23]. In gnomAD, which used LOFTEE without MAF threshold, about 40% of genes had >10 233 predicted LOF variants [41].

234

235 **Phenotypes of interest**

We will test the association of selected variants with a set of 15 clinical and three neuroradiological

phenotypes of interest in the UKB. These phenotypes were selected based on their frequency in the

- 238 general population and the UKB, the plausibility of their association with type I interferon
- 239 upregulation, and from type I interferonopathy clinical presentations (including Mendelian and
- 240 sporadic diseases). The International Classification of Diseases (ICD) diagnostic codes and UKB fields

Page 11 of 31

for each phenotype are presented in Supplemental table 3. Genes associated with ≥1 phenotype of
interest will be assessed for their association with 196 clinical phenotypes to help interpret their
relevance (Supplemental table 4). We manually grouped ICD-coded diagnoses by pathophysiology to
reduce multiple testing and improve power for less common conditions. As part of the phenome
analysis, we will test two stroke definitions developed by Rannikmäe et al [44] to help explain potential
misclassifications.

247 Health-related outcomes were captured through self-completed questionnaires followed by a 248 nurse-led interview on past medical history (at baseline in all and during follow-up for some 249 participants), as well as data linkage with ICD-coded hospital admissions from National Health Service 250 (NHS) registries (primary or secondary diagnoses; ICD v9 and v10) and national death registries 251 (primary and secondary causes of death; ICD v10). Diagnostic codes from primary care (Read codes v2 252 and v3) are available in a subset of participants (~45.8%). Cancer diagnoses (ICD v9 and v10) are 253 available through data linkage with national cancer registries. Stroke diagnoses from hospital and death 254 registries have a high sensitivity (point estimate range: 88-94%) and specificity (>99%) [45]. Most 255 stroke cases in the UKB are from hospital and death registries, although $\sim 27\%$ are self-reported without 256 coded diagnosis [44]. Self-reported strokes have a lower sensitivity (79%) but maintain a high 257 specificity (99%) [46]. In-hospital and death records for all-cause dementia in the UKB have a positive 258 predicted value of ~85% [47].

We will define phenotypes in the UKB using algorithmically defined (or adjudicated) outcomes (v2.0), first diagnostic occurrences, and cancer registries. Algorithmically defined outcomes are custom diagnostic classification schemes developed by the UKB from self-reports, hospital admissions and death registries to optimize their positive predictive value. First diagnostic occurrences map clinical terms from all available sources into ICD v10 codes (apart from cancer registries). Algorithmically defined outcomes and first diagnostic occurrences will be combined to identify any stroke, ischemic

Page 12 of 31

stroke, intracerebral haemorrhage, subarachnoid haemorrhage, all-cause dementia, Alzheimer's
disease, vascular dementia, Parkinson's disease and myocardial infarction [48]. We chose to combine
these two fields to capture primary care events (not included in algorithmically defined outcomes),
which is expected to increase the number of cases from 0.7% (n=55) for all-cause dementia to 11.4%
(n=1,376) for ischemic stroke. First diagnostic occurrences will be used alone for other non-cancerous
conditions. Data from cancer registries will be used to define malignant neoplasms.

271 We will define three neuroradiological phenotypes: total white matter hyperintensity (WMH) 272 volume, total brain (grey plus white matter) volume, and hippocampal grey matter (mean) volume [49]. 273 Brain magnetic resonance imaging (MRI) scans were obtained in ~42k participants on 3T Siemens 274 Skyra scanners running VD13A SP4 with a standard Siemens 32-channel radio-frequency receiver 275 head coil. The UKB MRI quality control pipeline includes a pre-processing step to correct for head 276 motion and other artifacts followed by automated identification of equipment failure and excessive 277 artifacts [50]. We will normalize WMH and hippocampal grey matter volumes for head size using the 278 UKB scaling factor derived from the external surface of the skull. The normalized total brain volume is 279 available as an imaging-derived phenotype. We will log-transform WMH volumes given their right-280 skewed (log-normal) distribution.

281 The total WMH volume of presumed vascular origin per individual was generated by an image-282 processing pipeline [50] followed by a segmentation algorithm (the Brain Intensity Abnormality 283 Classification Algorithm tool; BIANCA) using both T1- and T2-weighted/fluid-attenuated inversion 284 recovery (FLAIR) sequences [51]. The algorithm results in high volumetric agreement (intraclass 285 correlation coefficient = 0.99) and very good spatial overlap index (dice similarity index = 0.76) with 286 manual segmentation. Total brain (including the cerebellum and the brainstem, as low as space-based 287 brain masking allows) and regional brain volumes were extracted using tissue-segmented images 288 obtained from an automated algorithm (FMRIB's Automated Segmentation Tool; FAST) [52] and

Page 13 of 31

passed on to the SIENAX analysis pipeline to accurately measure volumetric phenotypes (relative
mean error in brain volume = 0.4%) [53]. We will use the mean hippocampal grey matter volume (from

right and left hippocampi) as this radiological marker of hippocampal atrophy is associated with

- 292 memory loss and progression to Alzheimer's disease [54].
- 293

294 Statistical analyses

Our primary (score-based) analysis will test the association of all selected genes modelled into a rare variant genetic risk score (RVGRS) with individual phenotypes. We will regress each phenotype on standardized scores using logistic and linear regressions for binary and continuous outcomes, respectively. We will adapt a previously described methodology [55] to define our score as the weighted sum of the number of variants per individual *i* and gene $g(V_{i,g})$, given a set of *M* genes:

$$RVGRS_i = \sum_{g=1}^{M} \beta_g V_{i,g}$$

301 Gene-level weights will be allocated from theoretical variant effects on the type I interferon cascade. 302 For example, LOF variants in genes encoding negative regulators will receive a positive weight (+1) as 303 they are expected to upregulate the cascade, whereas those in genes encoding positive regulators or 304 effectors will receive a negative weight (-1). We chose this conservative weighting method given the 305 technical limitations of weighting variants from a transcriptomic signature (unavailable in the UKB) or 306 a proteomic profile (no measurement of type I interferon in the UKB Olink proteomics).

Our secondary analysis will test gene-level associations with individual phenotypes using the
optimal sequence kernel association test (SKAT-O) framed into SAIGE-GENE+. The SKAT-O test
leverages the advantages of burden tests and SKAT through a linear combination of their test statistics,
the relative contribution of which are estimated by a correlation term [56]. We chose this method to
balance the need to maximise power for genes that have a higher proportion of causal variants
satisfying the burden test assumption, while preserving power for genes that may have fewer causal
Page 14 of 31

313	variants (or variants with heterogeneous effects) despite our filtering strategy. The SAIGE-GENE+
314	method builds upon SKAT-O to reduce type I error inflation for very rare variants in large biobanks
315	with unbalanced case-control ratios, reduce computational resources and account for sample
316	relatedness [57]. We will use a relatedness coefficient cut-off of ≥ 0.125 (up to third-degree relatedness)
317	in SAIGE-GENE+, and perform our analyses using the open-source R package SAIGE
318	(https://github.com/saigegit/SAIGE). We will include the first 10 genetic principal components in the
319	gene-level (combined with the generalized mixed model approach in SAIGE-GENE+) and RVGRS
320	models to control for population structure [58], in addition to adjusting for age and sex [59]. We will
321	also adjust for scanner site in neuroradiological analyses to control for potential technical confounding
322	[60]. We will run separate gene-level tests for LOF/dominant negative and GOF variants to account for
323	their anticipated opposite effect directions. As SKAT-O is designed to test the overall gene-trait
324	association and does not produce effect sizes, variant-level effects will be obtained through separate
325	logistic and linear regressions to help interpret p-values (as in Genebass). Genetic units with <10
326	carriers of any variant in the UKB will not be analysed to preserve power.
327	Our score and individual genes will be tested for their association with each phenotype of
328	interest (n=18), and those with ≥ 1 statistically significant association with any phenotype of interest
329	will be tested for associations across the phenome (n=196). We will interpret statistical significance in
330	our score-based analysis with a Bonferroni-corrected p-value threshold to account for multiple testing
331	across phenotypes (phenotypes of interest: $0.05/18=2.78\times10^{-3}$; phenome: $0.05/196=2.55\times10^{-4}$). We will
332	interpret statistical significance in our gene-level analysis similarly, with a more stringent correction to
333	account for multiple testing across genes and phenotypes (0.05/[# phenotypes x # gene-level units])
334	[61]. Our analyses will be conducted on the UK Biobank Research Analysis Platform [62]. We present
335	our pre-planned sensitivity analyses in Supplemental methods 2 .

336

337 Power calculations

We performed a statistical power analysis for our gene-level tests and phenotypes of interest with SKAT-O using the *SKAT* package (v2.2.5) for R. Our results and analysis parameters are presented in **Figure 3** and detailed in **Supplemental methods 3**. Gene-level tests for lupus and vascular dementia have the lowest powers overall although they increase to reasonable values in more optimistic scenarios. Other cardiovascular and inflammatory outcomes have the highest power throughout all scenarios.

344

345 **DISCUSSION**

Comprehensive phenotyping of interferonopathy variant carriers may expand the clinical spectrum of 346 347 genetic type I interferonopathies and help understand the biological relevance of type I interferon 348 dysregulation in the general population. Importantly, large population-based assessments of 349 interferonopathy carriers are lacking. Our study will leverage knowledge of Mendelian diseases of type 350 I interferon to develop an informed, hypothesis-driven candidate pathway approach to investigate the 351 frequency and phenotype associations of low-grade type I interferon dysregulation in the UKB. Our 352 results will help understand the clinical spectrum of genetic type I interferonopathies, and will provide 353 insights into the role of type I interferon in sporadic conditions.

Recent meta-analyses of genome-wide association studies (GWASs) have strengthened the case of inflammatory contributors to stroke and dementia. The largest cross-ancestry GWAS meta-analysis on stroke to date identified 89 independent genomic risk loci, of which two newly reported loci were located near or within genes involved in type I interferon regulation or signalling (*PTPN11* and *TAP1*) (63]. A recent large GWAS meta-analysis on Alzheimer's disease and related dementias identified 33 known and 42 new genomic loci, for which a pathway analysis exposed significant gene sets related to immunity, including macrophage and microglia activation [64]. The nearest genes of two new lead

Page 16 of 31

variants, *SHARPIN* and *RBCK1*, encode essential components of the linear ubiquitin chain assembly
 complex (LUBAC), involved in NF-κB activation. Despite these discoveries, GWASs are unable to
 identify rarer alleles that may carry important information on the biology of complex traits, while most
 variants in genomic risk loci are mapped outside coding regions and have unknown regulatory
 functions [65, 66].

366

367 Strengths and limitations

368 The UKB is the largest whole-exome sequencing project to date, markedly improving power to detect 369 associations from a limited number of rare, functional variants [67]. Our informed approach will 370 leverage current knowledge on type I interferon biology to reduce noise and test biologically plausible 371 hypotheses. This contrasts with prior hypothesis-free phenome-wide association studies using rare 372 variants in the UKB such as Genebass [42] and PheWAS [68], which did not include clinical 373 annotations, used uncurated phenotypes, introduced greater multiple-testing burden (~4.5k and ~17k phenotypes tested in Genebass and PheWAS, respectively), and often used small sample sizes (as few 374 375 as 30 cases/phenotype in PheWAS). The UKB also enables phenotyping from multiple sources, 376 improving the classification accuracy for stroke and dementia as compared to studies using minimal 377 phenotyping (e.g., case definition from self-reported dementia in relatives) [64]. 378 Our study, however, will have some limitations. First, we expect that our weighting strategy 379 based on theoretical knowledge will introduce noise into our score. We were technically unable to 380 reliably assign empirical weights because of the lack of relevant transcript or protein measurements in 381 the UKB. We anticipate this noise will be reduced by carefully selecting genes for which variants have 382 a higher likelihood of functional and clinical consequences. We will also test genes individually as an

alternative that does not mandate weights. Second, we anticipate some degree of residual pleiotropy

384 through overlapping inflammatory and non-inflammatory pathways despite our careful curation of

- genes to increase specificity to the type I interferon cascade. We will, however, explore the relevance
 of pleiotropic effects on our results with a proteomic sensitivity analysis (Supplemental methods 2).
 Third, although we will optimize our overall power by carefully selecting clinically relevant genes and
- 388 functional variants, our power will likely remain lower for rarer phenotypes.

389

390 ETHICS AND DISSEMINATION

- 391 The UKB has received ethical approval from the North West Multicentre Research Ethics Committee,
- 392 and all participants provided written informed consent at recruitment. This research will be conducted
- using the UKB Resource under application number 93,160. We expect to disseminate our results in a
- 394 peer-reviewed journal and at an international cardiovascular conference.

395 FIGURE LEGENDS

Figure 1. Graphical summary of the study methodology.

397 This summary illustrates the three main steps of the study: i) genes of interest will be identified from a

- 398 literature review and Gene Ontology, followed by clinical and functional filtering, ii) variants of
- interest will be included based on their clinical relevance and functional annotations, and iii) the
- 400 association of variants and phenotypes will be tested with a rare variant genetic risk score and gene-
- 401 level tests. Abbreviations: LOFTEE, Loss-Of-Function Transcript Effect Estimator; M-CAP,
- 402 Mendelian Clinically Applicable Pathogenicity score; NCBI, National Center for Biotechnology
- 403 Information; OMIM, Online Mendelian Inheritance in Man; OQFE, Original Quality Functionally
- 404 Equivalent; pLOF, predicted loss-of-function; SKAT-O, optimal sequence kernel association test; VEP,

405 Variant Effect Predictor. Created with BioRender.com.

406

407 Figure 2. Overview of the interferon cascade.

408 Graphical overview of the main steps involved in interferon regulation and signalling. Endogenous 409 nucleases (blue circle sectors) remove nucleic acids (red confetti) that can trigger interferon production. 410 Abnormal accumulation of endogenous material through impaired regulation (box 1) and viral nucleic 411 acids (not shown) can trigger interferon production through linkage to i) toll-like receptor sensors at the 412 cell membrane surface (not shown) and at endosomes, and ii) cytoplasmic sensors (box 2). Interferons 413 are sensed by cell surface receptors specific to types I (heterodimer with subunits IFNAR1 and 414 IFNAR2), II (heterotetramer with two IFNGR1 and two IFNGR2 subunits) and III (heterodimer with 415 subunits IFNLR1 and IL-10R2) ligands. Signal transduction and intracellular signalling through JAK-416 STAT activates the transcription of interferon-stimulated genes (box 3). Abbreviations: GAS, gamma-417 activated sequence; IFN, interferon; IRF, interferon regulatory factor; ISG, interferon-stimulated gene; 418 ISRE, interferon-stimulated response element; TLR, toll-like receptor. Created with BioRender.com.

419 Figure 3. Power calculations for gene-level tests with phenotypes of interest using SKAT-O.

- 420 The power calculation assumes an α =1.11x10⁻⁵, a genetic sampling length of 2,962 bp, a MAF <0.1%, 421 an empirical optimal correlation coefficient, and sample sizes observed in the UKB. Abbreviations: 422 AD, Alzheimer's disease; AF, atrial fibrillation; bp, base pairs; BrV, total brain (grey plus white 423 matter) volume; CKD, chronic kidney disease; Dem, all-cause dementia; HipV, hippocampal grey 424 matter volume (average); IBD, inflammatory bowel disease; ICH, intracerebral haemorrhage; IHD, 425 ischemic heart disease; IS, ischemic stroke; MAF, minor allele frequency; PAD, peripheral artery 426 disease; RA, rheumatoid arthritis; SAH, subarachnoid haemorrhage; SCTD, systemic connective tissue 427 disorder; SLE, systemic lupus erythematosus; VascD, vascular dementia; WMHV, total white matter
- 428 hyperintensity volume.

TABLES

Table 1. Ovid MEDLINE search strategy.

Line	Entry	Records		
Interf	Interferon concept			
1	(cytokine* adj (inflammat* or proinflammat*)).tw.	422		
2	IFN*.ti.	15433		
3	Interferons/	25640		
4	1 or 2 or 3	40607		
Regulation concept				
5	(regulat* or metabolism or biology or function).ti	1191801		
Review design hedge				
6	meta analysis.mp,pt. or review.pt. or search:.tw.	3563440		
Combine concepts				
7	4 and 5 and 6	390		
8	7 not ((exp animal/ or nonhuman/) not exp human/)	357		
9	8 not (case study/ or case report/)	356		
10	limit 9 to dt=20000101-20230110	214		
11	limit 10 to English language	194		

This table presents the search strategy conducted in Ovid MEDLINE on 10 January 2023. Abbreviations: adj, adjacent; dt, create date; exp, explode; mp, multi-purpose fields; pt, publication type; ti, text word in title; tw, text word in title and abstract.

429 **REFERENCES**

- 430 1. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host
- 431 defenses. *Annu Rev Immunol* 2014;32:513-45. doi: 10.1146/annurev-immunol-032713-120231
- 432 [published Online First: 2014/02/22]
- 433 2. Crow MK, Olferiev M, Kirou KA. Type I Interferons in Autoimmune Disease. Annual Review of
- 434 Pathology: Mechanisms of Disease 2019;14(1):369-93. doi: 10.1146/annurev-pathol-020117 435 043952
- 3. Boshuizen MC, de Winther MP. Interferons as Essential Modulators of Atherosclerosis. *Arterioscler Thromb Vasc Biol* 2015;35(7):1579-88. doi: 10.1161/ATVBAHA.115.305464 [published
- 438 Online First: 2015/05/09]
- 4. Kavanagh D, McGlasson S, Jury A, et al. Type I interferon causes thrombotic microangiopathy by a
 dose-dependent toxic effect on the microvasculature. *Blood* 2016;128(24):2824-33. doi:
- 441 10.1182/blood-2016-05-715987 [published Online First: 2016/09/25]
- 442 5. de Jong HJI, Kingwell E, Shirani A, et al. Evaluating the safety of beta-interferons in MS: A series
- 443 of nested case-control studies. *Neurology* 2017;88(24):2310-20. doi:
- 444 10.1212/WNL.000000000004037 [published Online First: 20170512]
- 6. Gao N, Kong M, Li X, et al. Systemic Lupus Erythematosus and Cardiovascular Disease: A
- 446 Mendelian Randomization Study. *Front Immunol* 2022;13:908831. doi:
- 447 10.3389/fimmu.2022.908831 [published Online First: 2022/06/24]
- 448 7. de Amorim LC, Maia FM, Rodrigues CE. Stroke in systemic lupus erythematosus and
- 449 antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment.
- 450 *Lupus* 2017;26(5):529-36. doi: 10.1177/0961203316688784 [published Online First:
- 451 2017/04/11]

- 452 8. Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: The type I
- 453 interferonopathies, a conceptual overview. *J Exp Med* 2016;213(12):2527-38. doi:
- 454 10.1084/jem.20161596 [published Online First: 2016/11/09]
- 455 9. Crow YJ, Manel N. Aicardi-Goutieres syndrome and the type I interferonopathies. *Nat Rev Immunol*
- 456 2015;15(7):429-40. doi: 10.1038/nri3850 [published Online First: 2015/06/09]
- 457 10. Rice GI, Kasher PR, Forte GM, et al. Mutations in ADAR1 cause Aicardi-Goutieres syndrome
- 458 associated with a type I interferon signature. *Nat Genet* 2012;44(11):1243-8. doi:
- 459 10.1038/ng.2414 [published Online First: 2012/09/25]
- 460 11. Briggs TA, Rice GI, Adib N, et al. Spondyloenchondrodysplasia Due to Mutations in ACP5: A
- 461 Comprehensive Survey. *Journal of Clinical Immunology* 2016;36(3):220-34. doi:
- 462 10.1007/s10875-016-0252-y
- 463 12. Gunther C, Kind B, Reijns MA, et al. Defective removal of ribonucleotides from DNA promotes
 464 systemic autoimmunity. *J Clin Invest* 2015;125(1):413-24. doi: 10.1172/JCI78001 [published
 465 Online First: 20141215]
- 466 13. Kelly PJ, Lemmens R, Tsivgoulis G. Inflammation and Stroke Risk: A New Target for Prevention.
- 467 *Stroke* 2021:STROKEAHA121034388. doi: 10.1161/STROKEAHA.121.034388 [published
 468 Online First: 2021/06/25]
- 469 14. Little J, Higgins JP, Ioannidis JP, et al. Strengthening the reporting of genetic association studies
 470 (STREGA): an extension of the STROBE statement. *Eur J Epidemiol* 2009;24(1):37-55. doi:
- 471 10.1007/s10654-008-9302-y [published Online First: 2009/02/04]
- 15. Hewitt J, Walters M, Padmanabhan S, et al. Cohort profile of the UK Biobank: diagnosis and
- 473 characteristics of cerebrovascular disease. *BMJ Open* 2016;6(3):e009161. doi:
- 474 10.1136/bmjopen-2015-009161 [published Online First: 2016/03/24]

- 475 16. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the
- 476 causes of a wide range of complex diseases of middle and old age. *PLoS Med*
- 477 2015;12(3):e1001779. doi: 10.1371/journal.pmed.1001779 [published Online First: 2015/04/01]
- 478 17. UK Biobank. UK Biobank Whole Exome Sequencing Protocol (September 2021) 2022 [Available
- 479 from: <u>https://biobank.ndph.ox.ac.uk/showcase/refer.cgi?id=915</u>] accessed 10 October, 2022.
- 480 18. Regier AA, Farjoun Y, Larson DE, et al. Functional equivalence of genome sequencing analysis
- 481 pipelines enables harmonized variant calling across human genetics projects. *Nat Commun*
- 482 2018;9(1):4038. doi: 10.1038/s41467-018-06159-4 [published Online First: 2018/10/04]
- 483 19. Yun T, Li H, Chang P-C, et al. Accurate, scalable cohort variant calls using DeepVariant and
- 484 GLnexus. *Bioinformatics* 2021;36(24):5582-89. doi: 10.1093/bioinformatics/btaa1081
- 20. Poplin R, Chang P-C, Alexander D, et al. A universal SNP and small-indel variant caller using deep
 neural networks. *Nature Biotechnology* 2018;36(10):983-87. doi: 10.1038/nbt.4235
- 487 21. Lin Y-L, Chang P-C, Hsu C, et al. Comparison of GATK and DeepVariant by trio sequencing.
 488 *Scientific Reports* 2022;12(1):1809. doi: 10.1038/s41598-022-05833-4
- 489 22. Lin MF, Rodeh O, Penn J, et al. GLnexus: joint variant calling for large cohort sequencing. *bioRxiv*490 2018:343970. doi: 10.1101/343970
- 491 23. Szustakowski JD, Balasubramanian S, Kvikstad E, et al. Advancing human genetics research and
- 492 drug discovery through exome sequencing of the UK Biobank. *Nature Genetics*
- 493 2021;53(7):942-48. doi: 10.1038/s41588-021-00885-0
- 494 24. UK Biobank. UK Biobank Whole Exome Sequencing 300k Release: Analysis Best Practices 2021
- 495 [Available from: <u>https://www.ukbiobank.ac.uk/media/najcnoaz/access_064-uk-biobank-exome-</u>
 496 release-faq_v11-1_final-002.pdf] accessed 10 October, 2022.

- 497 25. Hofmeister RJ, Ribeiro DM, Rubinacci S, et al. Accurate rare variant phasing of whole-genome and
- 498 whole-exome sequencing data in the UK Biobank. *bioRxiv* 2022:2022.10.19.512867. doi:
- 499 10.1101/2022.10.19.512867
- 500 26. Sharafeldin N, Slattery ML, Liu Q, et al. A Candidate-Pathway Approach to Identify Gene-
- 501 Environment Interactions: Analyses of Colon Cancer Risk and Survival. J Natl Cancer Inst
- 502 2015;107(9) doi: 10.1093/jnci/djv160 [published Online First: 20150613]
- 503 27. Gene Ontology Consortium. The Gene Ontology resource: enriching a GOld mine. *Nucleic Acids* 504 *Res* 2021;49(D1):D325-D34. doi: 10.1093/nar/gkaa1113
- 505 28. Health Information Research Unit (McMaster University). Hedges 2016 [Available from:
- 506
 https://hiru.mcmaster.ca/hiru/HIRU_Hedges_MEDLINE_Strategies.aspx#Reviews] accessed

 507
 10 January, 2023.
- 508 29. Eleftheriou D, Brogan PA. Genetic interferonopathies: An overview. Best Pract Res Clin
- 509 *Rheumatol* 2017;31(4):441-59. doi: 10.1016/j.berh.2017.12.002 [published Online First:
- 510 2018/05/19]
- 511 30. Crow YJ, Stetson DB. The type I interferonopathies: 10 years on. *Nature Reviews Immunology*512 2022;22(8):471-83. doi: 10.1038/s41577-021-00633-9
- 513 31. Carbon S, Ireland A, Mungall CJ, et al. AmiGO: online access to ontology and annotation data.
- 514 *Bioinformatics* 2009;25(2):288-9. doi: 10.1093/bioinformatics/btn615 [published Online First: 515 20081125]
- 32. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The
 Gene Ontology Consortium. *Nat Genet* 2000;25(1):25-9. doi: 10.1038/75556
- 518 33. UniProt C. UniProt: the Universal Protein Knowledgebase in 2023. *Nucleic Acids Res* 2022 doi:
- 519 10.1093/nar/gkac1052 [published Online First: 20221121]

520 34. National Center for Biotechnology Information. Gene 2022 [Available from:

521 <u>https://www.ncbi.nlm.nih.gov/gene]</u> accessed October 14, 2022.

- 522 35. McKusick-Nathans Institute of Genetic Medicine Johns Hopkins University. Online Mendelian
- 523 Inheritance in Man (OMIM) [Available from: <u>https://omim.org/</u>] accessed November 1, 2022.
- 524 36. Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and
- supporting evidence. *Nucleic Acids Res* 2018;46(D1):D1062-D67. doi: 10.1093/nar/gkx1153
 [published Online First: 2017/11/23]
- 527 37. Yao Y, Higgs BW, Morehouse C, et al. Development of Potential Pharmacodynamic and
- 528 Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus
- 529 Erythematosus. *Hum Genomics Proteomics* 2009;2009 doi: 10.4061/2009/374312 [published
 530 Online First: 20091117]
- 550 Onnie Filst. 20091117]
- 53138. Backwell L, Marsh JA. Diverse Molecular Mechanisms Underlying Pathogenic Protein Mutations:
- 532Beyond the Loss-of-Function Paradigm. Annu Rev Genomics Hum Genet 2022;23:475-98. doi:

533 10.1146/annurev-genom-111221-103208 [published Online First: 20220408]

- 534 39. Shameer K, Tripathi LP, Kalari KR, et al. Interpreting functional effects of coding variants:
- 535 challenges in proteome-scale prediction, annotation and assessment. *Brief Bioinform*
- 536 2016;17(5):841-62. doi: 10.1093/bib/bbv084 [published Online First: 2015/10/24]
- 40. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. *Genome Biol*

538 2016;17(1):122. doi: 10.1186/s13059-016-0974-4 [published Online First: 2016/06/09]

- 539 41. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from
- 540 variation in 141,456 humans. *Nature* 2020;581(7809):434-43. doi: 10.1038/s41586-020-2308-7
- 541 [published Online First: 2020/05/29]

- 542 42. Karczewski KJ, Solomonson M, Chao KR, et al. Systematic single-variant and gene-based
- 543 association testing of thousands of phenotypes in 394,841 UK Biobank exomes. *Cell Genomics*
- 544 2022;2(9):100168. doi: <u>https://doi.org/10.1016/j.xgen.2022.100168</u>
- 545 43. Jagadeesh KA, Wenger AM, Berger MJ, et al. M-CAP eliminates a majority of variants of
- 546 uncertain significance in clinical exomes at high sensitivity. *Nature Genetics* 2016;48(12):1581-
- 547 86. doi: 10.1038/ng.3703
- 548 44. Rannikmae K, Rawlik K, Ferguson AC, et al. Physician-Confirmed and Administrative Definitions
- 549 of Stroke in UK Biobank Reflect the Same Underlying Genetic Trait. *Front Neurol*
- 550 2021;12:787107. doi: 10.3389/fneur.2021.787107 [published Online First: 2022/02/22]
- 45. Woodfield R, Grant I, Group UKBSO, et al. Accuracy of Electronic Health Record Data for
- 552 Identifying Stroke Cases in Large-Scale Epidemiological Studies: A Systematic Review from
- the UK Biobank Stroke Outcomes Group. *PLoS One* 2015;10(10):e0140533. doi:
- 554 10.1371/journal.pone.0140533 [published Online First: 2015/10/27]
- 46. Jones WJ, Williams LS, Meschia JF. Validating the Questionnaire for Verifying Stroke-Free Status
- 556 (QVSFS) by neurological history and examination. *Stroke* 2001;32(10):2232-6. doi:
- 557 10.1161/hs1001.096191
- 47. Wilkinson T, Schnier C, Bush K, et al. Identifying dementia outcomes in UK Biobank: a validation
 study of primary care, hospital admissions and mortality data. *Eur J Epidemiol* 2019;34(6):557-

560 65. doi: 10.1007/s10654-019-00499-1 [published Online First: 2019/02/27]

- 48. UK Biobank Outcome Adjudication Group. Algorithmically-defined outcomes (version 2.0): UK
 Biobank, 2022:28.
- 49. Shang X, Zhang X, Huang Y, et al. Association of a wide range of individual chronic diseases and
 their multimorbidity with brain volumes in the UK Biobank: A cross-sectional study.
- 565 *eClinicalMedicine* 2022;47 doi: 10.1016/j.eclinm.2022.101413

- 566 50. Alfaro-Almagro F, Jenkinson M, Bangerter NK, et al. Image processing and Quality Control for the
- 567 first 10,000 brain imaging datasets from UK Biobank. *Neuroimage* 2018;166:400-24. doi:
- 568 10.1016/j.neuroimage.2017.10.034 [published Online First: 2017/10/29]
- 569 51. Griffanti L, Zamboni G, Khan A, et al. BIANCA (Brain Intensity AbNormality Classification
- 570 Algorithm): A new tool for automated segmentation of white matter hyperintensities.
- 571 *Neuroimage* 2016;141:191-205. doi: 10.1016/j.neuroimage.2016.07.018 [published Online
- 572 First: 2016/07/13]
- 573 52. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random
- 574 field model and the expectation-maximization algorithm. *IEEE Trans Med Imaging*
- 575 2001;20(1):45-57. doi: 10.1109/42.906424
- 576 53. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross577 sectional brain change analysis. *Neuroimage* 2002;17(1):479-89. doi: 10.1006/nimg.2002.1040
- 578 54. Mielke MM, Okonkwo OC, Oishi K, et al. Fornix integrity and hippocampal volume predict
- 579 memory decline and progression to Alzheimer's disease. *Alzheimers Dement* 2012;8(2):105-13.
- 580 doi: 10.1016/j.jalz.2011.05.2416
- 55. Lali R, Chong M, Omidi A, et al. Calibrated rare variant genetic risk scores for complex disease
 prediction using large exome sequence repositories. *Nat Commun* 2021;12(1):5852. doi:

583 10.1038/s41467-021-26114-0 [published Online First: 2021/10/08]

- 584 56. Lee S, Wu MC, Lin X. Optimal tests for rare variant effects in sequencing association studies.
- 585 *Biostatistics* 2012;13(4):762-75. doi: 10.1093/biostatistics/kxs014 [published Online First:
 586 20120614]
- 587 57. Zhou W, Bi W, Zhao Z, et al. SAIGE-GENE+ improves the efficiency and accuracy of set-based
 588 rare variant association tests. *Nat Genet* 2022;54(10):1466-69. doi: 10.1038/s41588-022-01178589 w [published Online First: 20220922]

- 590 58. Zhang Y, Pan W. Principal component regression and linear mixed model in association analysis of
- 591 structured samples: competitors or complements? *Genet Epidemiol* 2015;39(3):149-55. doi:
- 592 10.1002/gepi.21879 [published Online First: 20141223]
- 593 59. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in
- 594 epidemiologic studies. *Epidemiology* 2009;20(4):488-95. doi: 10.1097/EDE.0b013e3181a819a1
- 595 [published Online First: 2009/06/16]
- 596 60. Alfaro-Almagro F, McCarthy P, Afyouni S, et al. Confound modelling in UK Biobank brain
- 597 imaging. *Neuroimage* 2021;224:117002. doi: 10.1016/j.neuroimage.2020.117002 [published
 598 Online First: 20200602]
- 599 61. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA
- 600 2003;100(16):9440-5. doi: 10.1073/pnas.1530509100 [published Online First: 2003/07/29]
- 601 62. UK Biobank. Research Analysis Platform: Tools Library 2022 [Available from:
- 602 <u>https://dnanexus.gitbook.io/uk-biobank-rap/working-on-the-research-analysis-platform/tools-</u>
- 603 <u>library</u>] accessed November 16, 2022.
- 604 63. Mishra A, Malik R, Hachiya T, et al. Stroke genetics informs drug discovery and risk prediction
 605 across ancestries. *Nature* 2022 doi: 10.1038/s41586-022-05165-3 [published Online First:
 606 2022/10/01]
- 607 64. Bellenguez C, Küçükali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer's
 608 disease and related dementias. *Nature Genetics* 2022;54(4):412-36. doi: 10.1038/s41588-022-
- 609 01024-z
- 65. Uffelmann E, Huang QQ, Munung NS, et al. Genome-wide association studies. *Nature Reviews Methods Primers* 2021;1(1):59. doi: 10.1038/s43586-021-00056-9

- 612 66. Tam V, Patel N, Turcotte M, et al. Benefits and limitations of genome-wide association studies. *Nat*
- 613 *Rev Genet* 2019;20(8):467-84. doi: 10.1038/s41576-019-0127-1 [published Online First:

614 2019/05/10]

- 615 67. UK Biobank. Final data release from the world's largest whole exome sequencing project 2022
- 616 [Available from: <u>https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/final-data-</u>
- 617 release-from-the-world-s-largest-whole-exome-sequencing-project] accessed 10 October, 2022.
- 618 68. Wang Q, Dhindsa RS, Carss K, et al. Rare variant contribution to human disease in 281,104 UK
- 619 Biobank exomes. *Nature* 2021;597(7877):527-32. doi: 10.1038/s41586-021-03855-y [published
- 620 Online First: 2021/08/11]

621

622 AUTHORS' CONTRIBUTIONS

BR planned the study, performed the analyses, and drafted the protocol. WW and DH had a major role
in the conception of the study, provided methodological and content expertise, and revised the
manuscript. MC, RW, SM, KR, DM, JM, RB and YC provided methodological and content expertise,
and had a major role in revising the manuscript. BR is the guarantor of the content of the study.

627

628 FUNDING STATEMENT

629 BR is supported by the Centre for Clinical Brain Sciences of the University of Edinburgh (Rowling &

630 Dr Hugh S P Binnie scholarship), the Canadian Institutes of Health Research (CIHR; Doctoral Foreign

631 Study Award, DFD-187711), the Fonds de recherche du Québec – Santé and the Ministère de la Santé

- 632 et des Services sociaux du Québec (joint clinician-investigator fellowship), and the Power Corporation
- of Canada Chair in Neurosciences of the University of Montreal (research scholarship). KR is

634 supported by Health Data Research UK (Rutherford fellowship MR/S004130/1), and the Wellcome

- 635 Trust-University of Edinburgh Institutional Strategic Support Fund. SM is supported by the Clayco
- 636 Foundation for RVCL research. DM is supported by the Wellcome Trust (216767/Z/19/Z). RB is
- 637 supported by an Association of British Neurologists Clinical Research Training Fellowship funded by
- the Guarantors of Brain. DH is supported by a Wellcome Trust Senior Research Fellowship
- 639 (215621/Z/19/Z) and the Medical Research Foundation. WW is supported by the Chief Scientist Office
- of the Scottish Government (CAF/17/01), the UK Alzheimer's Society and the Stroke Association, the
- 641 National Institute for Health and Care Research (NIHR) and the National Institutes of Health (NIH).

Funding sources had no role in the design or conduct of the study.

643

644 **COMPETING INTERESTS STATEMENT**

645 All authors have nothing to declare.









D - 50% causal variants

40.6 39.8 37

20.9

0.8

21.1 20.9

8.4 7.1

0.4

0.7

